← The Wire
OLMANasdaq
Olema Pharmaceuticals, Inc.
Pharmaceutical Preparations · DE · CIK 1750284
Olema develops targeted therapies for breast cancer, including its lead candidate palazestrant
red 8-K · 90d
$862M
Market cap
$12.20
Last close
+7.1%
1D
+22.0%
5D
1.4M
Volume
Price · last 39 sessions-16.6%
May 4L $9.19 · H $15.19Jun 29
121
Total filings
Jun 23, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 23, 20268-KReg FD Disclosure · Company UpdateMay 26, 20268-KReg FD Disclosure · Company UpdateMay 21, 202610-Q10-QMay 12, 20268-KResults of OperationsMay 12, 20268-KMaterial Agreement · New Debt / ObligationMay 1, 2026DEFA14ADEFA14AApr 29, 2026DEF 14ADEF 14AApr 29, 20268-KExecutive Change · Reg FD DisclosureApr 29, 202610-K10-KMar 16, 20268-KResults of OperationsMar 16, 20268-KExecutive ChangeJan 30, 20268-KResults of Operations · Reg FD DisclosureJan 12, 20268-KCompany UpdateNov 19, 2025424B5424B5Nov 19, 2025424B5424B5Nov 18, 20258-KCompany UpdateNov 18, 202510-Q10-QNov 10, 20258-KResults of OperationsNov 10, 20258-KReg FD Disclosure · Company UpdateOct 20, 20258-KReg FD Disclosure · Company UpdateSep 2, 202510-Q10-QAug 11, 20258-KResults of Operations · Reg FD DisclosureAug 11, 20258-KShareholder VoteJun 13, 202510-Q10-QMay 13, 20258-KResults of OperationsMay 13, 2025DEFA14ADEFA14AApr 28, 2025DEF 14ADEF 14AApr 28, 202510-K10-KMar 18, 20258-KResults of OperationsMar 18, 20258-KReg FD DisclosureMar 5, 2025424B5424B5Jan 15, 20258-KReg FD DisclosureJan 13, 20258-KEquity IssuanceJan 10, 2025SC 13GSC 13GDec 11, 20248-KReg FD Disclosure · Company UpdateDec 10, 20248-KMaterial Agreement · Equity IssuanceDec 2, 202410-Q10-QNov 12, 20248-KResults of OperationsNov 12, 20248-KReg FD Disclosure · Company UpdateSep 27, 202410-Q10-QAug 6, 20248-KResults of OperationsAug 6, 20248-KMaterial Agreement · New Debt / ObligationJul 2, 20248-KShareholder VoteJun 14, 2024SC 13GOLEMA PHARMACEUTICALS INC.Jun 14, 20248-KReg FD Disclosure · Company UpdateMay 15, 202410-Q10-QMay 8, 20248-KResults of OperationsMay 8, 2024DEFA14ADEFA14AApr 26, 2024DEF 14ADEF 14AApr 26, 2024SC 13GSC 13GMar 22, 202410-K10-KMar 11, 20248-KResults of OperationsMar 11, 2024SC 13GSC 13GJan 29, 20248-KReg FD DisclosureJan 8, 20248-KReg FD Disclosure · Company UpdateJan 8, 20248-KMaterial Agreement · Company UpdateJan 5, 2024424B5424B5Jan 5, 20248-KReg FD DisclosureDec 6, 20238-KReg FD Disclosure · Company UpdateDec 5, 202310-Q10-QNov 7, 20238-KResults of OperationsNov 7, 20238-KReg FD Disclosure · Company UpdateOct 23, 20238-K/AExecutive Change · Reg FD DisclosureOct 18, 20238-KMaterial Agreement · Reg FD DisclosureOct 17, 20238-KMaterial Agreement · Reg FD DisclosureOct 10, 20238-KMaterial Agreement · New Debt / ObligationSep 5, 202310-Q10-QAug 8, 20238-KResults of OperationsAug 8, 20238-KShareholder VoteJun 21, 20238-KCompany UpdateMay 11, 202310-Q10-QMay 9, 20238-KResults of OperationsMay 9, 2023DEFA14ADEFA14AApr 28, 2023DEF 14ADEF 14AApr 28, 2023SC 13GSC 13GApr 10, 20238-KReg FD DisclosureMar 10, 2023424B5424B5Mar 9, 202310-K10-KMar 9, 20238-KResults of OperationsMar 9, 2023
Insider Activity
In the 90 days to Mar 4, 2026: 6 sold $24.4M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 4, 2026 | Mitchell ShawnteCHIEF LEGAL OFFICER | Sell | 24,767 | $24.25 | $601K |
| Mar 4, 2026 | Mitchell ShawnteCHIEF LEGAL OFFICER | Sell | 233 | $24.69 | $6K |
| Mar 3, 2026 | Mitchell ShawnteCHIEF LEGAL OFFICER | Sell | 15,000 | $23.01 | $345K |
| Jan 20, 2026 | Harmon CyrusDirector | Sell | 10,000 | $26.88 | $269K |
| Jan 15, 2026 | Kovacs Shane William CharlesCH. OPERATING & FINANCIAL OFF. | Sell | 100,000 | $28.73 | $2.9M |
| Jan 14, 2026 | Myles David C.CH. DISCOV. & NON-CLIN DEV OFF | Sell | 35,003 | $28.99 | $1.0M |
| Jan 14, 2026 | Myles David C.CH. DISCOV. & NON-CLIN DEV OFF | Sell | 14,997 | $28.60 | $429K |
| Jan 14, 2026 | Harmon CyrusDirector | Sell | 3,489 | $29.12 | $102K |
| Jan 13, 2026 | Myles David C.CH. DISCOV. & NON-CLIN DEV OFF | Sell | 49,800 | $27.60 | $1.4M |
| Jan 13, 2026 | Kovacs Shane William CharlesCH. OPERATING & FINANCIAL OFF. | Sell | 3,822 | $28.01 | $107K |
| Jan 13, 2026 | Myles David C.CH. DISCOV. & NON-CLIN DEV OFF | Sell | 200 | $28.49 | $6K |
| Jan 12, 2026 | Myles David C.CH. DISCOV. & NON-CLIN DEV OFF | Sell | 10,000 | $28.34 | $283K |
| Dec 23, 2025 | Zojwalla NaseemChief Medical Officer | Sell | 99,509 | $27.66 | $2.8M |
| Dec 22, 2025 | Zojwalla NaseemChief Medical Officer | Sell | 100,000 | $28.04 | $2.8M |
| Dec 22, 2025 | Harmon CyrusDirector | Sell | 2,881 | $28.53 | $82K |
| Dec 19, 2025 | Clark Ian TDirector | Sell | 193,056 | $29.71 | $5.7M |
| Dec 19, 2025 | Zojwalla NaseemChief Medical Officer | Sell | 57,079 | $28.03 | $1.6M |
| Dec 19, 2025 | Myles David C.CH. DISCOV. & NON-CLIN DEV OFF | Sell | 43,729 | $30.40 | $1.3M |
| Dec 19, 2025 | Clark Ian TDirector | Sell | 41,840 | $30.48 | $1.3M |
| Dec 19, 2025 | Clark Ian TDirector | Sell | 29,904 | $28.83 | $862K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance